<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790916</url>
  </required_header>
  <id_info>
    <org_study_id>BP42698</org_study_id>
    <secondary_id>2020-003990-23</secondary_id>
    <nct_id>NCT04790916</nct_id>
  </id_info>
  <brief_title>Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel-Group, Phase 2 Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse&#xD;
      following forced corticosteroid (CCS) tapering as measured by the hazard ratio between&#xD;
      RO7049665 7.5 milligrams (mg) and placebo arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse for RO7049665 7.5 mg Versus Placebo</measure>
    <time_frame>From randomization (Day 1) up to relapse or end of the study (up to approximately 25 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Up to end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Up to end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Immunoglobulin G (IgG)</measure>
    <time_frame>Up to end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse for RO7049665 3.5 mg Versus Placebo</measure>
    <time_frame>From Randomization (Day 1) up to relapse or end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-drug Antibody (ADA) Emergence and Neutralizing Potential</measure>
    <time_frame>Up to end of the study (up to approximately 25 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Autoimmune Chronic Hepatitis</condition>
  <arm_group>
    <arm_group_label>RO7049665 3.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7049665 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7049665</intervention_name>
    <description>RO7049665, subcutaneous injection, Q2W.</description>
    <arm_group_label>RO7049665 3.5 mg</arm_group_label>
    <arm_group_label>RO7049665 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>RO7049665-matching placebo, subcutaneous injection, Q2W.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a definite diagnosis of AIH (type 1, 2 and 3) as per simplified or&#xD;
             revised original diagnostic criteria&#xD;
&#xD;
          -  Participants who have been in biochemical remission for &gt; 2 years (or less if&#xD;
             according to the local practice) prior to randomization&#xD;
&#xD;
          -  Participants who have been on stable treatment (corticosteroids [CCSs] +/-&#xD;
             non-specific immunosuppressants [NSIs]) for at least 3 months prior to randomization&#xD;
             and who have not had a dose increase in the previous 6 months prior to randomization&#xD;
&#xD;
          -  No signs of liver inflammation on a liver biopsy taken no more than 12 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Participants with AIH who have previously not attempted (or not attempted in the last&#xD;
             3 years, if this is the local practice) to taper CCSs to 0 mg/day&#xD;
&#xD;
          -  Body mass index within the range of 18-35 kilograms per meter square (kg/m^2)&#xD;
&#xD;
          -  Women of childbearing potential who agree to remain abstinent or use at least one&#xD;
             acceptable contraceptive method during the treatment period and for at least 28 days&#xD;
             after the final dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with cirrhosis (F4 fibrosis by FibroscanÂ®) with significant impairment of&#xD;
             liver function (Child Pugh category B or C)&#xD;
&#xD;
          -  Any other autoimmune disease requiring immunomodulating treatment&#xD;
&#xD;
          -  History of infection with hepatitis B, human immunodeficiency virus, active hepatitis&#xD;
             C virus (HCV) infection, detection of replicating cytomegalovirus (CMV) or&#xD;
             Epstein-Barr virus (EBV)&#xD;
&#xD;
          -  Active infections requiring systemic therapy with antibiotic, antiviral, or antifungal&#xD;
             treatment or febrile illness within 7 days before Day-1&#xD;
&#xD;
          -  History of primary or acquired immunodeficiency&#xD;
&#xD;
          -  Pregnant or lactating female participants&#xD;
&#xD;
          -  Symptomatic herpes zoster within 3 months prior to screening&#xD;
&#xD;
          -  History of active or latent tuberculosis or a positive Quantiferon Gold test&#xD;
&#xD;
          -  History of clinically significant severe drug allergies, multiple drug allergies,&#xD;
             allergy to any constituent of the product, or intolerance to topical steroids&#xD;
&#xD;
          -  Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell&#xD;
             or squamous epithelial carcinomas of the skin that have been resected with no evidence&#xD;
             of metastatic disease for 3 years and in situ carcinoma of the cervix that was&#xD;
             completely removed surgically. Breast cancer within the past 10 years&#xD;
&#xD;
          -  Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic,&#xD;
             endocrine, or gastrointestinal disorders&#xD;
&#xD;
          -  Any condition or disease detected during the medical interview/physical examination&#xD;
             that would render the participant unsuitable for the study, place the participant at&#xD;
             undue risk, or interfere with the ability of the participant to complete the study in&#xD;
             the opinion of the Investigator&#xD;
&#xD;
          -  CCSs of &lt;5 mg/day, or &lt;2.5 mg CCSs plus immune suppressant, or &lt;3 mg/day budesonide&#xD;
             with or without immune suppressant&#xD;
&#xD;
          -  CCSs &gt;20 mg/day or &gt;9 mg/day budesonide&#xD;
&#xD;
          -  Non-specific immunosuppressant (NSI) daily dose higher than recommended standard of&#xD;
             care therapy&#xD;
&#xD;
          -  T or B cell-depleting therapy within the last 12 months or T- or B-cell number below&#xD;
             normal due to depleting therapy&#xD;
&#xD;
          -  Leukocyte apheresis within 12 weeks of screening&#xD;
&#xD;
          -  Donation of blood or blood products in excess of 500 milliliters (mL) within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Exposure to any investigational treatment within 6 months prior to Day 1&#xD;
&#xD;
          -  Abnormal hematologic, hepatic enzyme, hepatic function, or biochemistry values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital - Professor Stuart Roberts' Clinic - The Alfred Centre Location</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite de Montreal - Centre Hospitalier de l'Universite de Montreal CHUM - Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Zeitz Centrum fÃ¼r Seltene Erkrankungen ZSE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Saverio De Bellis; Anatomia Patologica</name>
      <address>
        <city>Castellana Grotte</city>
        <state>Puglia</state>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital; division of pulmonology</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Liver Center</name>
      <address>
        <city>Seoul</city>
        <zip>KOR</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - location AMC</name>
      <address>
        <city>Amstermdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud Universiteit - Radboud Universitair Medisch Centrum Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Real</name>
      <address>
        <city>Vila Real</city>
        <zip>5000-508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

